Phase I/II trial of hypoxia-inducible factor-2α suggests efficacy in patients with advanced clear cell renal cell carcinoma

Patients with clear cell metastatic renal cell carcinoma could benefit from dual immune checkpoint inhibition plus stereotactic radiotherapy, with further investigation of the combination warranted

Patients with cisplatin-ineligible locally advanced or metastatic urothelial carcinoma have shown rapid, durable responses and good tolerability to first-line enfortumab vedotin plus pembrolizumab

Patients with metastatic castration-resistant prostate cancer have better pain and quality of life outcomes with cabazitaxel than with abiraterone or enzalutamide 

Men with metastatic castration-resistant prostate cancer who have progressed on enzalutamide may benefit from adding pembrolizumab to their regimen

Men might have significantly better 5-year androgen deprivation therapy-free survival with metastasis-directed stereotactic body radiotherapy or surgery than with surveillance 

Patients with metastatic nonsquamous non-small-cell lung cancer derive quality of life benefits from the addition of pembrolizumab to first-line chemotherapy

Study data support maximal resection of contrast-enhanced tumour in all patients with glioblastoma and maximal resection of non-contrast-enhanced tumour in younger patients, regardless of molecular subgroup